AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: VRAYLAR (AbbVie Inc.) (vraylar.com)
Vraylar.com is a high-substance, low-BS site that prioritizes regulatory transparency and clinical data over marketing air. The presence of ‘fluff’ is limited to emotional patient framing which is standard for consumer pharma, but the forensic medical data provides a massive concrete floor. This is a benchmark for how regulated industries should present substance.
To further reduce the BS score, the marketing team should rotate the ‘breakthrough’ power word in the H1s for more condition-specific nouns. The site could integrate the specific ClinicalTrials.gov registration numbers directly into the condition pages to provide a direct path to raw data. Finally, ensuring that ‘Kami’ and ‘Alec’ are marked up with Person schema in the structured data would close the remaining authority gap. The ‘US-VRA-230116test’ code in the Leave Site modal should be cleaned up to maintain technical credibility.
The Information Density is exceptionally high for a consumer-facing site, largely due to pharmaceutical regulatory requirements. While the H1 ‘Breaking through to relief is possible’ uses power words, it is immediately supported by specific data points such as ‘1.5 Million Patients Treated Since 2015’ and ‘FDA approval dates’ for four distinct indications (2015, 2019, 2022). The body substance ratio is high, with the ‘Important Safety Information’ and ‘Indications and Usage’ sections providing granular technical specifications on dosage (0.5 mg to 6 mg) and metabolic side effects. Concept repetition is present in the recurring use of the ‘breakthrough’ metaphor, but it is tied to specific medical conditions rather than vague ‘synergy’.
AI crawlers don't scroll, click, or wait — they take whatever the raw HTML gives them. Start your free crawl layer inspection and see whether your site is actually reachable in an AI native environment.
There is zero detectable semantic drift between the homepage and the sub-pages. The homepage establishes VRAYLAR as a treatment for Bipolar I and MDD, and the specific sub-pages (vraylar.com/amdd and vraylar.com/bipolar) deliver exactly on those promises with deep-dive clinical contexts. The target audience remains consistent across all pages, and the pricing/savings information on the ‘Savings Program’ page supports the ‘relief’ claim by providing a specific economic pathway ($0 for eligible patients).
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
The site avoids trust theatre entirely; the review_count is 0 across all pages, indicating the brand does not use unverified or curated customer stars. Instead, it relies on verifiable clinical proof, providing direct links to ‘Full Prescribing Information’ and the ‘FDA MedWatch’ reporting system. The site also includes a ‘For Healthcare Professionals’ certification gate, which serves as a technical signal of regulatory compliance rather than marketing fluff.
The proof density is high, with every major efficacy claim linked to a technical document or a regulatory milestone. Across the 4 pages analyzed, there are 8+ instances of specific evidence including FDA approval years, patient count metrics, and specific capsule strengths. The ratio of verifiable evidence to vague assertions is roughly 4:1, placing it in the top tier of information substance.
To see how the methodology translates into real diagnostic output, review a full executive level analysis applied to a global fashion retailer. View the Mango Executive SEO Strategy for a concrete example of how structural gaps, semantic weaknesses, and conversion friction are surfaced in practice.
The site exhibits a minor commodity fingerprint through the use of industry-standard cliches like ‘Real people, real stories’ and the ‘breakthrough’ value proposition. However, because the product is a specific molecular entity (cariprazine), the value proposition cannot be copy-pasted onto a competitor’s site without rendering the medical data factually incorrect. The template follows the standard pharmaceutical layout (Boxed Warnings, ISI footer), which is a functional requirement rather than a lack of brand originality.
Authority is robustly established through structured data and clear corporate identity. The schema_json correctly identifies the ‘creator’ as ‘AbbVie Inc.’ and utilizes the ‘MedicalWebPage’ and ‘Psychiatric’ specialty types. Patient stories are attributed to named individuals like ‘Kami’ and ‘Alec’ with full video transcripts provided, which is significantly more substantive than the anonymous testimonials found on high-BS sites.
There is no disconnect between marketing claims and demonstrated performance. Claims like ‘clinically proven to help relieve overall depression symptoms’ are immediately qualified with a double-dagger symbol leading to the specific FDA approval date (2022) and clinical context. The performance claims are bounded by extensive lists of contraindications and adverse reactions, which ironically increases the site’s substance score by providing a complete medical picture.
Medical Devices, Pharma & Biotech BS: VRAYLAR (AbbVie Inc.) (vraylar.com)
The website perfectly aligns with the Pharma and Biotech industry classification. Its content is dominated by regulatory-required disclosure, clinical indications, and pharmacovigilance mechanisms.
Before embeddings, before entities, before retrieval — the crawler must reach the text. Open the Crawlability & Indexation Guide to learn how access failures erase meaning long before interpretation begins.
“The score of 10 is driven by the heavy regulatory burden of the pharmaceutical industry, which forces a level of substance (ISI/Prescribing Info) that most industries avoid. Minor penalties were applied in Information Density for repetitive messaging and in Commodity Fingerprint for the use of standard pharma patient-story templates. Overall, the distance between the signal of 'relief' and the substance of 'clinical data' is minimal.”